About Advenza Global Limited
Data last updated: 21 December 2025
Advenza Global Limited is a public limited company based in Thane West, Maharashtra, India. It specialises in industrial enzymes and biochemicals, a part of the broader chemicals and materials sector. Incorporated on 17 February 2005, the company has been in operation for over 21 years.
Registered with ROC Mumbai under CIN U24230MH2005PTC151389.
Capital: an authorised share capital of ₹261 Cr and a paid-up capital of ₹259.48 Cr. Formerly known as Advanced Vital Enzymes Limited and Advanced Bio-Nutraceuticals Limited. It is led by directors including Jayesh Narendra Sheth and Radhika Pujara Ashish.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Lodha Supremus Ii Unit No.: 424 4Th F Road No. 22 Wagle Estate, Thane West, Maharashtra, India – 400604.
As per the financials filed for FY 2025, the company reported a revenue of ₹62.48 Cr, a decline of 57% compared to the previous year.
The company has a workforce of approximately 189 employees as per the latest available data.
The company is associated with 2 brands - Advenza, Advanced Enzyme Technologies. As per MCA filings, the company has satisfied charges of ₹5.75 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website advenza.co.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressLodha Supremus Ii Unit No.: 424 4Th F Road No. 22 Wagle Estate, Thane West, Maharashtra, India – 400604
-
IndustryChemicals and Materials, Industrial Enzymes & Biochemicals
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Advenza Global Limited
Advenza Global Limited has undergone 3 name changes throughout its history. The company was previously known as Advanced Vital Enzymes Limited, Advanced Bio-Nutraceuticals Limited, and Advenza Global Limited. The current legal name is Advenza Global Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Advenza Global Limited | Current |
| Advanced Vital Enzymes Limited | Previous |
| Advanced Bio-Nutraceuticals Limited | Previous |
CIN History of Advenza Global Limited
Advenza Global Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24230MH2005PLC151389, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230MH2005PLC151389 | Current |
| U24230MH2005PTC151389 | Previous |
| L24230MH2005PLC151389 | Previous |
Associated Brands with Advenza Global Limited
Advenza Global Limited operates two associated brands: Advenza and Advanced Enzyme Technologies. These brands represent Advenza Global Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures custom probiotic and enzyme solutions for human and animal health. | advenza.co.in | |
| Enzymes are manufactured for nutrition, food, feed, and textile industries. | advancedenzymes.com |
Competitors & Alternatives of Advenza Global Limited
Brands and companies operating in the same space as Advenza Global Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jubilant Life Sciences
|
Company offering a suite of R&D and manufacturing services for small molecules and generics | Noida, India, India | 1978 |
Akums
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
Nectar Lifesciences
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
Windlas
|
Biopharma regulatory affairs, quality control, and strategy services are provided. | Gurugram, India, India | 2001 |
Unither
|
Contract development and manufacturing organization for proprietary and generic drugs | Paris, France, France | 1993 |
Recipharm
|
Pharmaceutical development and manufacturing services are offered contractually. | Jordbro, Sweden, Sweden | 1995 |
CoreRx
|
CDMO with a focus on early phase drug product development | Clearwater, United States, United States | 2006 |
MedPharm
|
Topical and inhaled drug delivery formulations are developed and manufactured. | Guildford, United Kingdom, United Kingdom | 1998 |
Zivo Bioscience
|
Bioactive compounds from algal strain | Keego Harbor, United States, United States | 1983 |
Enzymotec
|
Bio-functional lipid ingredients are developed for nutritional and pharmaceutical uses. | Kfar Saba, Israel, Israel | 1998 |
Auditor Details of Advenza Global Limited
Advenza Global Limited is audited by S Lakhotia & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S Lakhotia & Associates | blur-value | blur-value | blur-value |
Board of Directors of Advenza Global Limited
Advenza Global Limited is currently managed by 10 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jayesh Narendra Sheth | Director | 08 Aug 2025 | 0 Years 11 Months | Current |
| Radhika Pujara Ashish | Director | 14 Sep 2015 | 10 Years 9 Months | Current |
| Divya Piyush Rathi | Director | 14 Sep 2015 | 10 Years 9 Months | Current |
| Bhavna Jain | Company Secretary | 23 Jun 2025 | 1 Years 0 Months | Current |
| Ashish Mulchand Gala | Director | 08 Aug 2025 | 0 Years 11 Months | Current |
|
Savita Chandrakumar Rathi
Also directs:
Atharva Green Ecotech Llp, Ashtavakra Properties Private Limited, Hastamalaka Properties Private Limited and 2 more
|
Director | 17 Feb 2005 | 21 Years 4 Months | Current |
Financials of Advenza Global Limited FY 2024 filings available
Advenza Global Limited reported revenue of ₹62.48 Cr (down 57% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Advenza Global Limited
As of FY 2023, Advenza Global Limited's shareholding pattern shows 99.99% by promoters, 0.01% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Advenza Global Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jan 2019 | Others | ₹3.75 Cr | Satisfied |
| 28 Oct 2015 | Hdfc Bank Limited | ₹1 Cr | Satisfied |
| 15 Oct 2015 | Hdfc Bank Limited | ₹1 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Advenza Global Limited
Advenza Global Limited has a workforce of 189 employees as of Mar 23, 2024.
Employee Count & EPFO Data of Advenza Global Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Advenza Global Limited
GSTIN & GST Filing Data of Advenza Global Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Advenza Global Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Advenza Global Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Advenza Global Limited
MSME Payment Delays by Advenza Global Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Advenza Global Limited
Subsidiaries & Group Companies of Advenza Global Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Advenza Global Limited with ownership details.
MCA Filings & Documents of Advenza Global Limited
MCA Filings & Documents of Advenza Global Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Advenza Global Limited
Frequently Asked Questions about Advenza Global Limited
Advenza Global Limited is an active public limited company in the chemicals and materials sector based in Thane West, Maharashtra, India. It was incorporated on 17 February 2005 (21+ years old) and is registered under CIN U24230MH2005PLC151389. The company has 189 employees.
Advenza Global Limited reported revenue of ₹62.48 Cr for FY 2025 (down 57.00% YoY).
The current directors of Advenza Global Limited are:
The primary industry of Advenza Global Limited is chemicals and materials. The company specifically operates in industrial enzymes and biochemicals. The company is currently active in this sector.
Advenza Global Limited can be reached at the registered office: Lodha Supremus Ii Unit No.: 424 4Th F Road No. 22 Wagle Estate, Thane West, Maharashtra, India – 400604, or through the website advenza.co.in.
The authorised capital is ₹261 Cr, and the paid-up capital is ₹259.48 Cr.